Two Phase 3 trials which were seeking to show the superiority of a new combination treatment for patients with age-related macular degeneration (AMD) compared with the use of the licenced drug Lucentis alone, have failed to show an added benefit. ---Subscribe to MedNous to access this article--- Company News Clinical Research
